Karyopharm Therapeutics Stock News

In the last trading session, 1.28 million Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares changed hands as the companys beta touched 0.01. With the companys per share price at $8.12 changed hands at -$0.37 or -4.36% during last session, the market valuation stood at $604.78M. KPTIs last price was a discount, traded about -121.67% off its 52-week Karyopharm Therapeutics Inc.s (NASDAQ: KPTI) Stock Could Appreciate By -232.51% Read More »

Could these health care stocks be buys on President Biden's latest vaccine mandate?

The stock price of Karyopharm Therapeutics Inc (NASDAQ: KPTI) increased 37.37% today. This is why it happened.

Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q3 2021 Results - Earnings Call Transcript

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -1.47% and 45.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s

Karyopharm Therapeutics has been on my watch list for several years. Sadly, my buy conditions never manifested for me to establish a position. Now I am looking for an entry. I believe Karyopharm's cur

SHANGHAI and HONG KONG, Aug. 23, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing an

Investors need to pay close attention to Karyopharm Therapeutics (KPTI) stock based on the movements in the options market lately.

Karyopharm Therapeutics Inc. (KPTI) CEO Richard Paulson on Q2 2021 Results - Earnings Call Transcript

The stock price of Karyopharm Therapeutics Inc. (Nasdaq: KPTI) increased by over 7% pre-market. This is why it happened.

NEWTON, Mass., Aug. 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Pauls

NEWTON, Mass., Aug. 2, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensa

NEWTON, Mass., July 29, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will rep

At the mid-year mark, our contributors give updates on their picks.

SHANGHAI  and  HONG KONG , July 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developi